Navigation Links
BMP Sunstone Announces Participation in June Investor Conferences
Date:6/23/2008

PLYMOUTH MEETING, Pa., June 23 /Xinhua-PRNewswire/ -- BMP Sunstone Corporation (Nasdaq: BJGP; "BMP Sunstone" or the "Company") today announced that the Company will present at the following conferences:

1. The Piper Jaffray Europe Conference, held in London. Management is currently scheduled to present on June 25, 2008, at 10:00 am local time and hold one-on-one meetings the same day at the ANdAZ Hotel (formerly Great Eastern Hotel); and

2. The Jefferies Annual Healthcare Conference, held in New York. Management is currently scheduled to present on June 25, 2008, at 9:00 am ET and hold one-on-one meetings the same day.

Listeners may access live webcasts of both presentations by visiting the investor relations portion of the Company's website at http://www.bmpsunstone.com. Investors interested in attending these events should contact their institutional sales representatives.

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio- chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Penns
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
2. BMP Sunstone to Report First Quarter 2008 Financial Results
3. BMP Sunstone Announces Participation in May Investor Conferences
4. BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief
5. BMP Sunstone Reports First Quarter 2008 Financial Results
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- ... (MTF) -- the largest survey on teen drug abuse ... underscores that teens, intentional abuse of prescription (Rx) and ... concern, with an alarming number of young people abusing ... Teen Abuse of Medication Continues to Be ...
(Date:12/14/2009)... SANTA ANA, Calif., Dec. 14 Grubb & Ellis ... directors has authorized a daily distribution to stockholders of record ... the period commencing on Jan. 1, 2010 and ending on ... on 365 days in the calendar year and will be ... a purchase price of $10.00 per share. These distributions ...
(Date:12/14/2009)... On December 9, 2009, the United States ... position that private insurance companies are "plans" and therefore ... other federal courts have held that contracts issued by ... Title 18 Section 1347, US vs. Frost ... been held to be a "plan," because, as the ...
(Date:12/14/2009)... hadn,t spread, study finds , , MONDAY, Dec. 14 (HealthDay ... death in male colon cancer survivors, researchers report. , ... men who,d been treated for stage I, stage II ... (nonmetastatic cancer). Every two years, the men were sent ... disease diagnoses, as well as their physical activity. A ...
(Date:12/14/2009)... shouldn,t worry most users, researcher says , , MONDAY, Dec. ... may have a small but statistically significant increased risk ... the medications, a new study finds. , "But statistical ... Jordan W. Smoller, an associate professor of psychiatry at ... in the Dec. 14 issue of Archives of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... New Study in the Journal of Cosmetic Dermatology Finds Over-the-Counter ... for Helping to Clear Up Mild to Moderate EczemaEDISON, N.J., ... looking for a cost-effective way to control and heal this ... to consider. A new study in the March 2009 issue ...
... Surge in anxiety-linked hormone worsens blood sugar level, researchers suggest ... a key role in the development of type 2 diabetes ... has been given to the role of obesity in the ... important in this at-risk population," study co-author Anastasia Georgiades, of ...
... Inc. (NYSE: MED ) announced today that it ... for the period ended December 31, 2008 on Thursday, March ... Company will hold a conference call and web cast to ... a.m. ET.Interested parties can access the call by dialing (877) ...
... Minn., March 5 People across the country are now ... from Upsher-Smith Laboratories, Inc. AmLactin(R) Foot Cream Therapy provides ... dry and chapped feet because of its high concentration of ... Dry, chapped feet are the result of various factors ...
... Susan Dell Foundation awards grant totaling more than $3 ... -AUSTIN, Texas, March 5 The Michael & Susan ... The University of Texas School of Public ... expansion of the Coordinated Approach To Child Health (CATCH) ...
... Approvals for Intravenous Formulation of Temozolomide As Well As ... 5 Schering-Plough Corporation (NYSE: SGP ) ... FDA both approved the intravenous (IV) formulation of temozolomide ... of the drug. Temozolomide is marketed as TEMODAL(R) ...
Other Medicine News:Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 2Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 3Health News:Stress May Raise Diabetes Risk for Obese Black Women 2Health News:Medifast, Inc. to Announce Fourth Quarter and Fiscal Year 2008 Financial Results on Thursday, March 12, 2009 2Health News:New AmLactin(R) Foot Cream Immerses Feet in Moisture 2Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 2Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 3Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7
(Date:12/14/2009)... -- Travelers of Interstate 70 west of Indianapolis will ... more colorful when 10 multicolored art forms are installed ... going home , will eventually include 34 total pieces ... at Herron School of Art and Design, through the ... ,, Eli Lilly and Company (NYSE: LLY ...
(Date:12/14/2009)... Pa., Dec. 14 CPG International, ... engineered building products, introduces VYCOM, a rebranded ... the previous VYCOM Corporation and Scranton Products ... wholly recognized business unit within CPG International, ... Products Commercial. The VYCOM business unit has ...
(Date:12/14/2009)... Pharmaceutical Inc. (OTC Bulletin Board: OHRP) announced today ... in Irvine, CA, with offices also in New ... relations and corporate communications. Ohr Pharmaceutical is ... advanced drugs for underserved therapeutic needs. The Company ... markets: OHR/AVR118 for the treatment of Cachexia and ...
Breaking Medicine Technology:Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 1Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 1Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 3Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 4Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 5Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 1Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 2
... and REBETOL(R) will be the only available hepatitis C therapy, approved ... ... approval, KENILWORTH, ... that the Committee for Medicinal,Products for Human Use (CHMP) of the ...
... Sept. 24 Knopp Neurosciences Inc. ("Knopp"),today ... clinical trial of KNS-760704, a,small molecule therapy ... sclerosis (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ... ascending,dose study in healthy volunteers is being ...
Other Medicine Technology:European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 2European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 3European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 4European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 5European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 6European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 7European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 8Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 2Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: